King's College London

Research portal

Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study

Research output: Contribution to journalArticle

Standard

Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo : an observational study. / Ling, H Z; Jara, P G; Bisquera, A; Poon, L C; Nicolaides, K H; Kametas, N A.

In: BJOG, Vol. 127, No. 8, 01.07.2020, p. 1018-1025.

Research output: Contribution to journalArticle

Harvard

Ling, HZ, Jara, PG, Bisquera, A, Poon, LC, Nicolaides, KH & Kametas, NA 2020, 'Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study', BJOG, vol. 127, no. 8, pp. 1018-1025. https://doi.org/10.1111/1471-0528.16193

APA

Ling, H. Z., Jara, P. G., Bisquera, A., Poon, L. C., Nicolaides, K. H., & Kametas, N. A. (2020). Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study. BJOG, 127(8), 1018-1025. https://doi.org/10.1111/1471-0528.16193

Vancouver

Ling HZ, Jara PG, Bisquera A, Poon LC, Nicolaides KH, Kametas NA. Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study. BJOG. 2020 Jul 1;127(8):1018-1025. https://doi.org/10.1111/1471-0528.16193

Author

Ling, H Z ; Jara, P G ; Bisquera, A ; Poon, L C ; Nicolaides, K H ; Kametas, N A. / Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo : an observational study. In: BJOG. 2020 ; Vol. 127, No. 8. pp. 1018-1025.

Bibtex Download

@article{033d5a1ca9474a92807dfc25cbe4bf61,
title = "Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo: an observational study",
abstract = "OBJECTIVE: To compare maternal haemodynamics in women at low and high risk for preterm pre-eclampsia (PE), and between those at high risk who are randomised to aspirin or placebo.DESIGN: Prospective, longitudinal observational study.SETTING: Maternity units in six UK hospitals.POPULATION: Women participating in the Aspirin for Prevention of Preterm Pre-eclampsia (ASPRE) trial. The population comprised three groups of women: low risk for preterm PE (n = 1362), high risk for preterm PE treated with aspirin (n = 208), and high risk for preterm PE on placebo (n = 220).METHODS: Women had four visits during pregnancy: 11-14, 19-24, 30-34, and 35-37 weeks' gestation. Blood pressure was measured with a device validated for pregnancy, and PE and maternal haemodynamics were assessed with a bioreactance monitor at each visit. A multilevel linear mixed-effects analysis was performed to examine longitudinal changes of maternal haemodynamic variables, controlling for demographic characteristics, past medical history, and medication use.MAIN OUTCOME MEASURES: Longitudinal changes of cardiac output (CO), mean arterial pressure (MAP), and peripheral vascular resistance (PVR).RESULTS: The low-risk group demonstrated the expected changes with an increase in CO and reduction in MAP and PVR, with a quadratic change across gestation. In contrast, the high-risk groups had a declining CO, and higher MAP and PVR during pregnancy. The administration of aspirin did not appear to affect maternal haemodynamics.CONCLUSIONS: Women screened as high risk for preterm PE have a pathological cardiac adaptation to pregnancy and the prophylactic use of aspirin (150 mg oral daily from the first trimester) in this group may not alter this haemodynamic profile.TWEETABLE ABSTRACT: In women at high risk of pre-eclampsia, prophylactic use of aspirin may not alter the impaired maternal cardiac adaptation.",
keywords = "Aspirin, cardiac function, cardiac output, haemodynamics, peripheral vascular resistance, pre-eclampsia",
author = "Ling, {H Z} and Jara, {P G} and A Bisquera and Poon, {L C} and Nicolaides, {K H} and Kametas, {N A}",
note = "{\circledC} 2020 Royal College of Obstetricians and Gynaecologists.",
year = "2020",
month = "7",
day = "1",
doi = "10.1111/1471-0528.16193",
language = "English",
volume = "127",
pages = "1018--1025",
journal = "BJOG",
issn = "1470-0328",
publisher = "Blackwell Publishing Ltd",
number = "8",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Maternal cardiac function in women at high-risk for pre-eclampsia treated with 150 mg aspirin or placebo

T2 - an observational study

AU - Ling, H Z

AU - Jara, P G

AU - Bisquera, A

AU - Poon, L C

AU - Nicolaides, K H

AU - Kametas, N A

N1 - © 2020 Royal College of Obstetricians and Gynaecologists.

PY - 2020/7/1

Y1 - 2020/7/1

N2 - OBJECTIVE: To compare maternal haemodynamics in women at low and high risk for preterm pre-eclampsia (PE), and between those at high risk who are randomised to aspirin or placebo.DESIGN: Prospective, longitudinal observational study.SETTING: Maternity units in six UK hospitals.POPULATION: Women participating in the Aspirin for Prevention of Preterm Pre-eclampsia (ASPRE) trial. The population comprised three groups of women: low risk for preterm PE (n = 1362), high risk for preterm PE treated with aspirin (n = 208), and high risk for preterm PE on placebo (n = 220).METHODS: Women had four visits during pregnancy: 11-14, 19-24, 30-34, and 35-37 weeks' gestation. Blood pressure was measured with a device validated for pregnancy, and PE and maternal haemodynamics were assessed with a bioreactance monitor at each visit. A multilevel linear mixed-effects analysis was performed to examine longitudinal changes of maternal haemodynamic variables, controlling for demographic characteristics, past medical history, and medication use.MAIN OUTCOME MEASURES: Longitudinal changes of cardiac output (CO), mean arterial pressure (MAP), and peripheral vascular resistance (PVR).RESULTS: The low-risk group demonstrated the expected changes with an increase in CO and reduction in MAP and PVR, with a quadratic change across gestation. In contrast, the high-risk groups had a declining CO, and higher MAP and PVR during pregnancy. The administration of aspirin did not appear to affect maternal haemodynamics.CONCLUSIONS: Women screened as high risk for preterm PE have a pathological cardiac adaptation to pregnancy and the prophylactic use of aspirin (150 mg oral daily from the first trimester) in this group may not alter this haemodynamic profile.TWEETABLE ABSTRACT: In women at high risk of pre-eclampsia, prophylactic use of aspirin may not alter the impaired maternal cardiac adaptation.

AB - OBJECTIVE: To compare maternal haemodynamics in women at low and high risk for preterm pre-eclampsia (PE), and between those at high risk who are randomised to aspirin or placebo.DESIGN: Prospective, longitudinal observational study.SETTING: Maternity units in six UK hospitals.POPULATION: Women participating in the Aspirin for Prevention of Preterm Pre-eclampsia (ASPRE) trial. The population comprised three groups of women: low risk for preterm PE (n = 1362), high risk for preterm PE treated with aspirin (n = 208), and high risk for preterm PE on placebo (n = 220).METHODS: Women had four visits during pregnancy: 11-14, 19-24, 30-34, and 35-37 weeks' gestation. Blood pressure was measured with a device validated for pregnancy, and PE and maternal haemodynamics were assessed with a bioreactance monitor at each visit. A multilevel linear mixed-effects analysis was performed to examine longitudinal changes of maternal haemodynamic variables, controlling for demographic characteristics, past medical history, and medication use.MAIN OUTCOME MEASURES: Longitudinal changes of cardiac output (CO), mean arterial pressure (MAP), and peripheral vascular resistance (PVR).RESULTS: The low-risk group demonstrated the expected changes with an increase in CO and reduction in MAP and PVR, with a quadratic change across gestation. In contrast, the high-risk groups had a declining CO, and higher MAP and PVR during pregnancy. The administration of aspirin did not appear to affect maternal haemodynamics.CONCLUSIONS: Women screened as high risk for preterm PE have a pathological cardiac adaptation to pregnancy and the prophylactic use of aspirin (150 mg oral daily from the first trimester) in this group may not alter this haemodynamic profile.TWEETABLE ABSTRACT: In women at high risk of pre-eclampsia, prophylactic use of aspirin may not alter the impaired maternal cardiac adaptation.

KW - Aspirin

KW - cardiac function

KW - cardiac output

KW - haemodynamics

KW - peripheral vascular resistance

KW - pre-eclampsia

UR - http://www.scopus.com/inward/record.url?scp=85083357705&partnerID=8YFLogxK

U2 - 10.1111/1471-0528.16193

DO - 10.1111/1471-0528.16193

M3 - Article

C2 - 32133780

VL - 127

SP - 1018

EP - 1025

JO - BJOG

JF - BJOG

SN - 1470-0328

IS - 8

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454